DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+35.17%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$336M
AUM Growth
+$336M
(+9.2%)
Cap. Flow
-$49.4M
Cap. Flow
% of AUM
-14.71%
Top 10 Holdings %
Top 10 Hldgs %
56.86%
Holding
90
New
10
Increased
16
Reduced
26
Closed
16
Top Buys
| 1 |
Galapagos
GLPG
|
$3.56M |
| 2 |
Cassava Sciences
SAVA
|
$3.07M |
| 3 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$2.94M |
| 4 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$2.71M |
| 5 |
Venus Concept
VERO
|
$2.6M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$22.2M |
| 2 |
Arcturus Therapeutics
ARCT
|
$9.85M |
| 3 |
Fate Therapeutics
FATE
|
$9.47M |
| 4 |
BEAT
BioTelemetry, Inc.
BEAT
|
$3.99M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$2.94M |
Sector Composition
| 1 | Healthcare | 89.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Mersana Therapeutics
MRSN
$36.5M
| $1.31M | 0.39% | 49,263 -103,500 | -68% | -$2.75M |
|
|
BLUE
52
DELISTED
bluebird bio
BLUE
| $1.31M | 0.39% | 30,273 | – | – |
|
53
Arcus Biosciences
RCUS
$1.13B
| $1.29M | 0.38% | 49,600 -22,500 | -31% | -$584K |
|
|
VRNA
54
Verona Pharma
VRNA
$9.16B
| $1.13M | 0.34% | 161,507 | – | – |
|
55
Adicet Bio
ACET
$59.9M
| $1.09M | 0.32% | 77,577 +10,000 | +15% | +$141K |
|
|
PHAS
56
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $1.08M | 0.32% | 320,542 | – | – |
|
57
Larimar Therapeutics
LRMR
$310M
| $1.04M | 0.31% | 48,428 -30,727 | -39% | -$658K |
|
58
Revolution Medicines
RVMD
$7.1B
| $891K | 0.27% | +22,500 | New | +$891K |
|
|
PAND
59
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
| $865K | 0.26% | +58,222 | New | +$865K |
|
60
Masimo
MASI
$7.59B
| $805K | 0.24% | 3,000 | – | – |
|
61
Madrigal Pharmaceuticals
MDGL
$9.76B
| $734K | 0.22% | 6,600 | – | – |
|
62
NextCure
NXTC
$13.5M
| $709K | 0.21% | 65,000 -20,000 | -24% | -$218K |
|
63
Inogen
INGN
$216M
| $670K | 0.2% | 15,000 | – | – |
|
64
Athira Pharma
ATHA
$15.3M
| $566K | 0.17% | +16,531 | New | +$566K |
|
|
GNFT
65
Genfit
GNFT
$200M
| $549K | 0.16% | +114,341 | New | +$549K |
|
|
ISEE
66
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $476K | 0.14% | 68,951 -253,549 | -79% | -$1.75M |
|
|
RDUS
67
DELISTED
Radius Health, Inc.
RDUS
| $393K | 0.12% | 22,000 | – | – |
|
|
BEAT
68
DELISTED
BioTelemetry, Inc.
BEAT
| $375K | 0.11% | 5,200 -55,300 | -91% | -$3.99M |
|
69
Kura Oncology
KURA
$686M
| $294K | 0.09% | 9,000 -30,019 | -77% | -$981K |
|
70
Syndax Pharmaceuticals
SNDX
$1.41B
| $222K | 0.07% | 10,000 -92,713 | -90% | -$2.06M |
|
71
scPharmaceuticals
SCPH
$295M
| $206K | 0.06% | 38,891 -52,009 | -57% | -$275K |
|
72
Lineage Cell Therapeutics
LCTX
$267M
| $141K | 0.04% | 80,000 -15,000 | -16% | -$26.4K |
|
73
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – | -749,051 | Closed | -$2.57M |
|
74
Cardiff Oncology
CRDF
$140M
| – | – | -5,000 | Closed | -$71K |
|
75
Akebia Therapeutics
AKBA
$833M
| – | – | -341,779 | Closed | -$858K |
|